SCHEMBL1710619

SCHEMBL1710619

CC(C)(C)OC(=O)N1CCN(c2noc3c(F)cc(F)cc23)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.42
GPR119 Q8TDV5 2/20 0.42
GRIA1 P42261 1/20 0.42
TLR9 Q9NR96 1/20 0.41
PIK3CA P42336 1/20 0.40
HDAC4 P56524 1/20 0.40
GBA1 P04062 2/20 0.40
LMNA P02545 3/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SCD5 Q86SK9 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38
CXCR2 P25025 1/20 0.38
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964625 0.82 KIT (0.47) KITGRIA1TLR9HDAC4GBA1
SCHEMBL2420435 0.76 GPR119 (0.52) KITGPR119GRIA1LMNAMAPT
SCHEMBL30893588 0.76 GPR119 (0.52) KITGPR119GRIA1LMNAMAPT
SCHEMBL26123270 0.76 GBA1 (0.48) KITGPR119GRIA1HDAC4GBA1
SCHEMBL30546078 0.76 GBA1 (0.48) KITGPR119GRIA1HDAC4GBA1
SCHEMBL1864354 0.75 DRD2 (0.52)
SCHEMBL2976277 0.74 GBA1 (0.52) KITGPR119GBA1SMARCA2SMARCA4
SCHEMBL26121773 0.74 GBA1 (0.45) KITGPR119HDAC4GBA1LMNA
SCHEMBL30546256 0.74 GBA1 (0.45) KITGPR119HDAC4GBA1LMNA
SCHEMBL2311163 0.74 TLR9 (0.36) KITGPR119GRIA1TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344482-B1 BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS HOFFMANN LA ROCHE (CH) 2012-08-15 EP disclosed
EP-2344482-A1 BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-07-20 EP disclosed
US-7939535-B2 Benzo[D]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors HOFFMAN-LA ROCHE INC. (US) 2011-05-10 US disclosed
US-7939535-B2 Benzo[D]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors HOFFMAN-LA ROCHE INC. (US) 2011-05-10 US disclosed
WO-2010034646-A1 BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO disclosed
WO-2010034646-A1 BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO disclosed
US-20100075985-A1 BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) 2010-03-25 US disclosed
US-20100075985-A1 BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075985-A1 BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS DRD3, DRD2, DRD1 KIT 4236/4885GPR119 122/4885GRIA1 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.